Go to the list of all blogs
Jimmy Landsman's Avatar
published in Blogs
Jul 10, 2026
Direxion Daily Small Cap Bull 3X Shares (TNA) Advances +13% Amid Broadening Small-Cap Rally

Direxion Daily Small Cap Bull 3X Shares (TNA) Advances +13% Amid Broadening Small-Cap Rally

Key Takeaways

  • TNA surged approximately 13% over the past 30 days, amplifying a powerful rally in U.S. small-cap equities.
  • The Russell 2000 Index posted its strongest first-half performance since 1991, driven by the AI infrastructure buildout broadening beyond mega-cap technology names.
  • Semiconductor and semiconductor equipment companies within the small-cap universe were standout contributors, with several rising more than 400% year-to-date.
  • Improving earnings fundamentals and a historically wide valuation gap relative to large caps provided additional tailwinds for the small-cap rotation.
  • As a 3X daily leveraged ETF, TNA magnified these underlying index gains but also carries elevated volatility and compounding risks over holding periods longer than one day.

Understanding TNA and Its Exposure to the Russell 2000

Direxion Daily Small Cap Bull 3X Shares (TNA) is a leveraged exchange-traded fund that seeks daily investment results, before fees and expenses, of 300% of the performance of the Russell 2000 Index. The fund is designed for short-term tactical trading and is not intended as a buy-and-hold investment. TNA achieves its leveraged exposure primarily through swap agreements, futures contracts, and holdings of ETFs that track the index, most notably the iShares Russell 2000 ETF (IWM).

The underlying Russell 2000 Index measures the performance of approximately 2,000 small-capitalization companies within the broader Russell 3000 Index. As of March 31, 2026, the index’s largest sector weights were Industrials (18.3%), Health Care (17.7%), Financials (17.1%), and Information Technology (14.1%). Top index constituents included Bloom Energy, Coeur Mining, Fabrinet, and Credo Technology Group. TNA carries a net expense ratio of 1.05% and had assets under management (AUM) of approximately $1.44 billion.

TNA’s Recent Price Performance: 30 Days and the Quarter

Over the 30-day period ending in early July 2026, TNA advanced approximately 13%, reflecting a sustained rally in the underlying Russell 2000 Index amplified by the fund’s 3X daily leverage. The move was characterized by a trend-driven advance punctuated by periods of elevated intraday volatility, consistent with the behavior of a leveraged small-cap product during a strong directional market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Looking at the broader quarterly picture, TNA gained roughly 27% over the trailing three months. This performance extended a powerful multi-month uptrend for small-cap equities, with the Russell 2000 delivering its best first-half return in 35 years. The quarterly advance was supported by improving earnings estimates, a rotation out of mega-cap technology names, and growing conviction that the AI investment cycle is broadening to include smaller suppliers and infrastructure plays.

Factors Behind TNA’s 30-Day Advance

The primary catalyst behind TNA’s 30-day advance was the continued outperformance of U.S. small-cap stocks relative to large-cap benchmarks. The Russell 2000 Index extended its year-to-date gain to more than 20%, outpacing the S&P 500 by the widest margin for a first half since 2003. This rotation was fueled by several reinforcing factors.

First, the artificial intelligence investment boom continued to trickle down from mega-cap technology leaders to smaller companies across the AI supply chain. Semiconductor equipment makers, electronic components suppliers, and connectivity hardware providers within the Russell 2000 saw dramatic share price appreciation. Of the 50 best-performing stocks in the index year-to-date, 16 were semiconductor-related businesses.

Second, the valuation case for small caps remained compelling. After years of underperformance, the Russell 2000 entered 2026 trading at a historically wide discount to the S&P 500 on forward earnings multiples. This valuation gap began to close as investors rotated capital toward domestically oriented, cyclically sensitive companies.

Third, earnings fundamentals improved markedly. Consensus estimates for Russell 2000 earnings growth in 2026 rose from approximately 23% at the start of the year to 38% by midyear, reflecting stronger-than-expected profit recovery across industrials, financials, and technology hardware. Resilient U.S. economic growth, with GDP projected around 2.2% for 2026, provided a supportive macroeconomic backdrop.

Drivers of TNA’s Quarterly Performance

TNA’s quarterly performance was driven by a broader sector rotation and improving macroeconomic sentiment. The Russell 2000 gained approximately 21.5% in the second quarter alone, with all 11 sectors finishing in positive territory. Information Technology was the standout sector, followed by Industrials, Health Care, and Financials. Within technology, semiconductors and semiconductor equipment, software, and electronic components were the strongest industries.

The rally occurred despite a backdrop of persistent geopolitical uncertainty, including elevated energy prices tied to the U.S.-Iran conflict, and a Federal Reserve that held its policy rate steady at 3.50%–3.75%. Small caps historically exhibit higher sensitivity to interest rates due to greater reliance on floating-rate debt, but improving earnings power and AI-related demand helped offset this headwind. Institutional flows into small-cap ETFs also accelerated during the quarter, with passive index reconstitution adding mechanical buying pressure in June.

Using Tickeron’s AI Screener in Practice

In my own research process, I find Tickeron’s AI Screener to be a practical way to scan for opportunities across small-cap equities and related themes. The tool applies artificial intelligence to review thousands of stocks and ETFs using technical indicators, fundamental metrics, volatility patterns, and AI-generated trading signals. I can filter by industry, market capitalization, performance characteristics, or custom criteria to surface names that align with current market rotations or leverage strategies. For monitoring small-cap breakouts or sector shifts, it helps organize the data efficiently and supports more targeted analysis than manual review alone.

Key Factors to Monitor for TNA Going Forward

The trajectory of TNA in the coming months will be heavily influenced by the durability of the small-cap rally and the path of monetary policy. Several factors warrant close attention. The Federal Reserve’s interest rate decisions remain paramount; markets are pricing in a meaningful probability of at least one rate hike by September 2026, which would disproportionately pressure small-cap companies with floating-rate debt. Approximately 30% of Russell 2000 debt is floating rate, compared to just 7% for the S&P 500.

The sustainability of AI-related capital expenditures will also be critical. If the infrastructure buildout continues at its current pace, small-cap suppliers of semiconductor equipment, electrical components, and data center hardware could see further earnings upgrades. However, any slowdown in hyperscaler spending or a reassessment of AI return on investment could reverse these gains rapidly.

Additionally, the Russell 2000’s June 2026 reconstitution reduced the weight of AI infrastructure stocks within the index, which may moderate the pace of small-cap outperformance in the second half of the year. Earnings season will provide an important checkpoint on whether the upgraded growth expectations are being realized. Finally, geopolitical developments, particularly any escalation or resolution of the Middle East conflict, will influence energy prices and broader risk appetite. Investors using TNA should remain mindful that its 3X daily leverage amplifies both gains and losses, and the fund is designed for short-term trading rather than long-term portfolio allocation.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TNA

Contributor

My name is Jimmy, and I’m a financial analyst. I’m passionate about identifying the most promising ETFs for trading. Every day, I review hundreds of ETFs in search of trading and investment signals based on a variety of factors. I actively use technical analysis to identify short-term opportunities, including channels, indicators, support and resistance levels, and more. I also spend a great deal of time researching ETFs from a long-term investment perspective. My goal is to build a balanced ETF portfolio that combines investment-oriented and speculative ETFs and performs effectively during both market rallies and corrections.


TNA in downward trend: 10-day moving average broke below 50-day moving average on July 30, 2026

The 10-day moving average for TNA crossed bearishly below the 50-day moving average on July 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

TNA broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for TNA entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on TNA as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for TNA just turned positive on August 04, 2026. Looking at past instances where TNA's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

TNA moved above its 50-day moving average on August 03, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where TNA advanced for three days, in of 312 cases, the price rose further within the following month. The odds of a continued upward trend are .

Industry description

The investment seeks daily investment results, before fees and expenses, of 300% of the daily performance of the Russell 2000® Index. The fund invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and exchange-traded funds ("ETFs") that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index measures the performance of approximately 2,000 small-capitalization companies in the Russell 3000® Index, based on a combination of their market capitalization and current index membership. The fund is non-diversified.
View a ticker or compare two or three
TNA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Category Trading

Profile
Details
Category
Trading--Leveraged Equity
Address
Direxion Shares ETF Trust33 Whitehall Street,10th FloorNew York
Phone
866-476-7523
Web
http://www.direxioninvestments.com/
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.